Main Article Content
extensive study to enable the delivery of stavudine
in a once daily extended release formulation. The
in vitro evaluation has been performed with multiple
formulation options to enable the selection of the
right formulation system that renders once-a-day
delivery of stavudine, ensuring that zero order release
is maintained during the entire duration. As evidenced
by the generated data, the recommended formulation
(F9), appears to release approximately 4% of the drug
load every hour leading to a complete release of the
stavudine drug load by 24 hours.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.
Saravanakumar M, Venkateshwaramurthy N, Dhachinamoorthi D,
Perumal P. Extended release matrix tablets of stavudine: Formulation
and in vitro evaluation. Asian J Pharma 2010;4:219-23.
Zhou L, Kaul S, Liu-Kreyche P, Tran SB, Espina RR, Warrack BM, et al.
Disposition of [1'-(14)C]stavudine after oral administration to humans.
Drug Metab Dispos 2010;38:655-66.
Monif T, Tippabhotla SK, Garg M, Singla AK Comparative bioavailability/
bioequivalence of two different stavudine 40 mg capsule formulations:
A randomized, 2-way, crossover study in healthy volunteers under
fasting condition. Int J Clin Pharmacol Ther 2007;45:469-74.
Narang VS, Lulla A, Malhotra G, Purandare S. Bioequivalence evaluation
of two marketed brands of stavudine 40 mg capsules in healthy human
South African volunteers. Pharmacol Res 2004;50:511-6.
Waclawski AP, Sinko PJ. Oral absorption of anti-acquired immune
deficiency syndrome nucleoside analogues. 2. Carrier-mediated
intestinal transport of stavudine in rat and rabbit preparations. J Pharm
Hasegawa T, Juni K, Saneyoshi M, Kawaguchi T.Intestinal absorption
and first-pass elimination of 2', 3'-dideoxynucleosides following oral
administration in rats. Biol Pharm Bull 1996;19:599-603.
Ghosh A, Bhaumik UK, Bose A, Mandal U, Gowda V, Chatterjee B, et al.
Extended release dosage form of glipizide: Development and validation
of a level A in vitro-in vivo correlation. Biol Pharm Bull 2008;31:1946-51.
Dutta S, Qiu Y, Samara E, Cao G, Granneman GR. Once-a-day extendedrelease
dosage form of divalproex sodium III: Development and
validation of a Level A in vitro-in vivo correlation (IVIVC). J Pharm Sci
Etropolski MS, Okamoto A, Shapiro DY, Rauschkolb C. Dose conversion
between tapentadol immediate and extended release for low back pain.
Pain Physician 2010;13:61-70.
Jullien V, RaÃ¯s A, Urien S, Dimet J, Delaugerre C, Bouillon-Pichault M,
Rey E, Pons G, Blanche S, TrÃ©luyer JM. Age-related differences in the
pharmacokinetics of stavudine in 272 children from birth to 16 years:
A population analysis. Br J Clin Pharmacol.2007;64:105-9.